Key Highlights
- i2a leads in the development of automated microbiology diagnostics systems, setting industry standards with its SirScan2000 Automatic.
- The company's innovative software and reagents, such as the MHR-SIR gel medium and Inoclic, significantly enhance diagnostic efficiency and accuracy.
- i2a's extensive market presence in France and its expansion into international markets underscore its global competitiveness and adaptability.
- The company's focus on anticipating and meeting the needs of healthcare providers and researchers positions it as a forward-thinking leader in the diagnostics sector.
- i2a's commitment to innovation and excellence in microbiology diagnostics makes it a valuable partner for companies looking to enhance their diagnostic capabilities.
About i2a
i2a is a specialized microbiology diagnostics company based in Montpellier, France, founded in 1988. It has developed significant expertise in bacteriology, manufacturing and marketing instruments, software, and reagents. i2a is a leader in automated antibiogram readers in gel media, notably with the SirScan2000, and is the first company globally to design a fully automated gel system, the SirScan2000 Automatic. Their software offers a rich set of features, user-friendliness, and performance, while their reagents include innovative products like the MHR-SIR gel medium, Inoclic for inoculum standardization, and a range of high-performance antibiotic discs and diagnostic reagents.
i2a's competitive edge allows it to expand its offerings to include in vitro expertise systems, new instruments, software, and reagents, anticipating the needs of its clients and medical research across Europe, North America, and beyond. The company's innovative approach aims to make future realities a present-day achievement.
i2a has established itself as a key player in the microbiology diagnostics sector, serving 70% of France's hospital centers and also operating in the private market. Its commitment to innovation and excellence positions it as a leader in the field, with a focus on meeting the evolving needs of healthcare providers and researchers.
Why Contact i2a?
B2B professionals would contact i2a for its cutting-edge microbiology diagnostics solutions, which offer unparalleled efficiency and accuracy in diagnostic processes. The company's innovative products and global market presence make it an ideal partner for enhancing diagnostic capabilities in healthcare and research institutions.
Who Should Contact i2a for Business?
Sales teams targeting the healthcare and diagnostics sectors, recruiters seeking roles in microbiology and diagnostic technology, and partners offering complementary technologies or services in the medical field should reach out to i2a.
Categories
- microbiology diagnostics
- automated antibiogram readers
- SirScan2000
- diagnostic reagents
- healthcare technology
- laboratory equipment
- in vitro expertise
- medical diagnostics
- research and development
- innovation in diagnostics
More Medical Diagnostics Companies
Frequently Asked Questions
- How many employees does i2a have?
- i2a has approximately 145 employees.
- Where is i2a headquartered?
- Montpellier, France
- What industry is i2a in?
- i2a operates in Medical Diagnostics, Healthcare Technology, Laboratory Equipment.
- When was i2a founded?
- i2a was founded in 1988.
- Is i2a still active?
- Yes, i2a was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.
- How do I sell to i2a?
- Research i2a's priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details. Learn how Data Surfer helps.
Ready to Sell to i2a?
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Backed by startup programs from
Connect with i2a